The Impact of Antidepressant Dose and Class on Treatment Response in Pediatric Anxiety Disorders: A Meta-Analysis
Open accessAbstract
Objective To determine the trajectory and magnitude of antidepressant response as well as the effect of antidepressant class and dose on symptomatic improvement in pediatric anxiety disorders.Method Weekly symptom severity data were extracted from randomized, parallel group, placebo-controlled trials of selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs) in pediatric anxiety disorders. Treatment response was modeled for the standardized change in continuous measures of anxiety using Bayesian updating. Posterior distributions for each study served as informative conjugate prior to distributions update subsequent study posteriors. Change in symptom severity was evaluated as a function of time, class and, for SSRIs, standardized dose.Results Data from 9 trials (SSRIs: n = 5; SNRIs, n = 4) evaluating 7 medications in 1,673 youth were included. In the logarithmic model of treatment response, statistically, but not clinically, significant treatment effects emerged within 2 weeks of beginning treatment (standardized medication-placebo difference = -0.054, credible interval [CI] = -0.076 to -0.032, p = .005, approximate Cohen's d ≤ 0.2) and by week 6, clinically significant differences emerged (standardized medication-placebo difference = -0.120, CI = -0.142 to -0.097, p = .001, approximate Cohen's d = 0.44). Compared to SNRIs, SSRIs resulted in significantly greater improvement by the second week of treatment (p = .0268), and this advantage remained statistically significant through week 12 (all p values <.03). Improvement occurred earlier with high-dose SSRI treatment (week 2, p = .002) compared to low-dose treatment (week 10, p = .025), but SSRI dose did not have an impact on overall response trajectory (p > .18 for weeks 1-12).Conclusions In pediatric patients with generalized, separation, and/or social anxiety disorders, antidepressant-related improvement occurred early in the course of treatment, and SSRIs were associated with more rapid and greater improvement compared to SNRIs.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Gosman et al. results must be interpreted with caution due to moderate heterogeneity between studies and moderate risk of bias in a great proportion of included studies.
“These results must be interpreted with caution as one of the meta-analysis limitations is the moderate heterogeneity between studies and the moderate risk of bias that was found on a great proportion of the included studies.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [44]
The Results section (Selection of Studies and Study Characteristics; page not provided) says risk of bias was low across studies, contrary to the claim that a great proportion had moderate risk of bias. The Discussion acknowledges differences between studies but does not characterize their heterogeneity as moderate. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredGosman et al. found small differences between the medication's efficacy and their acceptability.
“Additionally, the authors also found small differences between the medication's efficacy and their acceptability.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [44]
The Results section (Effects of Antidepressant Class; page unavailable) reports significantly greater treatment response for SSRIs than SSNRIs, rather than small differences in efficacy. The paper does not report a comparison of acceptability across medications; its finding that medication–placebo attrition differences were under 10% concerns a different comparison. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredGosman et al. meta-analysis found all medications were more effective than placebo (p < .001) for all symptom domains and diagnoses.
“The authors found that all medications were more effective than placebo (p < .001)for all symptom domains and diagnoses.”
From The risks versus the benefits of pharmacological intervention in social anxiety disorder in children (2025) · cites this paper as [44]
The Results sections on treatment time course and antidepressant class report greater improvement with medication than placebo in pediatric anxiety disorders, including p<0.001 for both drug classes at week 12. They do not establish that every individual medication was more effective for every symptom domain and diagnosis; the reported significance also varies by time point. The cited paper is by Strawn et al., not Gosman et al. (Page numbers were not available in our copy.) (LLM, conf=0.87)
Experimental — accuracy not yet measuredAbout 50% of the ultimate response to antidepressant medications is observed within two weeks of treatment initiation, and maximum clinical effectiveness may take up to 6 to 8 weeks.
“While about 50% of the ultimate response is observed within two weeks of treatment initiation, maximum clinical effectiveness of antidepressant medications may take up to 6 to 8 weeks [24].”
From Psychological and Psychiatric Comorbidities in Youth with Serious Physical Illness (2022) · cites this paper as [24]
The Discussion reports that approximately 50% of the improvement observed at week 12 occurred by week 4, not week 2. The Results report a statistically significant difference from placebo at week 2 and a clinically significant difference by week 6, but do not establish that maximum effectiveness is reached at 6–8 weeks. These findings concern pediatric anxiety disorders, rather than antidepressant treatment generally. (LLM, conf=0.88)
Experimental — accuracy not yet measuredMost studies included in the meta-analysis showing that most improvements occurred in the first 6-8 weeks of SSRI therapy used fixed medication dosages.
“Most studies included in the meta-analysis showing that most improvements occurred in the first 6–8 weeks of SSRI therapy used fixed medication dosages”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
The Discussion (page unavailable) reports that improvement began early and approximately 50% of the week-12 treatment-related improvement occurred by week 4, supporting the claim’s broad timing point. It does not say that most included studies used fixed medication doses; the Discussion instead notes variation in trial dosing methods and calls for more fixed-dose trials. (LLM, conf=0.86)
Experimental — accuracy not yet measured
SSRI treatment effects begin to emerge within 2 weeks, sooner with higher doses.
“SSRI treatment effects begin to emerge within 2 weeks, sooner with higher doses [21]”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
Rates of failure to achieve remission in pediatric anxiety disorders are 60-80%.
“rates of failure to achieve remission are even higher (60–80%) [21, 22, 24–27, 30]”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
The Method (page not available) models treatment response as change in continuous anxiety-symptom scores, and the Results report improvement by antidepressant class. Searches for remission, failure to achieve remission, and 60–80% found no passage in our copy giving a remission-failure rate. (LLM, conf=0.74)
Experimental — accuracy not yet measuredSystematic reviews and meta-analyses have documented substantial therapeutic effects for psychotherapy, particularly CBT, and medication, especially SSRIs.
“Systematic reviews and meta-analyses have also documented substantial therapeutic effects for both psychotherapy, particularly CBT (Cognitive Behavioral Therapy) [18, 19], and medication, especially SSRIs (selective serotonin reuptake inhibitors) [20–22].”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
Remission rates are 40-50% for both CBT and SSRIs.
“Remission rates are lower, 40–50% for both CBT [24] and SSRIs [21, 22]”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
Acute treatment response rates are near 60% for both CBT and SSRIs.
“While response rates to acute treatment near 60% for both CBT [23] and SSRIs [21, 22] may seem encouraging”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
SSRI therapeutic response is significantly greater and faster than SNRI response.
“We selected the SSRI fluoxetine rather than an SNRI because SSRI therapeutic response is significantly greater and faster [21, 22, 129].”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
Approximately 50% of overall treatment-related improvement at week 12 occurs by week 4.
“approximately 50% of overall treatment-related improvement at week 12 occurs by week 4 [21]”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
Optimization of medication dosing often is not complete within the first 12 weeks, particularly for younger participants, and the effects of any given dose may not fully manifest for 12 weeks or more.
“Third, optimization of medication dosing often is not complete within the first 12 weeks, particularly for younger participants, and the effects of any given dose may not fully manifest for 12 weeks or more [21, 22, 129]; thus, the effects of Stage 1 dose increases may not manifest until Stage 2.”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
Approximately 40% of youth with pediatric anxiety disorders fail to respond to either SSRI or CBT.
“Approximately 40% of youth with pediatric anxiety disorders fail to respond to either SSRI or CBT [21–23]”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
Most of the studies included in the meta-analysis used fixed dosages.
“Most of the studies included in the meta-analysis used fixed dosages.”
From A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823 · see citing works
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859 · see citing works
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554 · see citing works
Gelman, A., Carlin, J. B., Stern, H. S., Dunson, D. B., Vehtari, A., & Rubin, D. B. (2013) · doi:10.1201/b16018 · Cited by 27,276 · see citing works
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · see citing works
Julia: A Fresh Approach to Numerical Computing
Bezanson, J., Edelman, A. S., Karpinski, S., & Shah, V. B. (2017) · SIAM Review · doi:10.1137/141000671 · Cited by 6,104 · see citing works
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
Kearns, G. L., Abdel‐Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S., & Kauffman, R. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035092 · Cited by 2,420 · see citing works
Understanding predictive information criteria for Bayesian models
Gelman, A., Hwang, J., & Vehtari, A. (2014) · Statistics and Computing · doi:10.1007/s11222-013-9416-2 · Cited by 2,104 · see citing works
A measure of anxiety symptoms among children
Spence, S. H. (1998) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(98)00034-5 · Cited by 1,928 · see citing works
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884 · see citing works
Pine, D. S., Cohen, P., Gurley, D., Brook, J., & Ma, Y. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.1.56 · Cited by 1,753 · see citing works
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442 · see citing works
Cipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734 · see citing works
Beesdo, K., Bittner, A., Pine, D. S., Stein, M. B., Höfler, M., Lieb, R., & Wittchen, H.-U. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.903 · Cited by 731 · see citing works
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588 · see citing works
Connolly, S. D., & Bernstein, G. A. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000246070.23695.06 · Cited by 548 · see citing works
Cuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., Beekman, A. T., & Reynolds, C. F. (2013) · World Psychiatry · doi:10.1002/wps.20038 · Cited by 540 · see citing works
The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties
P, T. R. U. O. P. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00006 · Cited by 532 · see citing works
Fluoxetine for the Treatment of Childhood Anxiety Disorders
Birmaher, B. B., Axelson, D., Monk, K., Kalas, C., Clark, D. B., Ehmann, M., Bridge, J. A., Heo, J., & Brent, D. A. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000037049.04952.9f · Cited by 380 · see citing works
Clinical characteristics of anxiety disordered youth
Kendall, P. C., Compton, S. N., Walkup, J. T., Birmaher, B., Albano, A. M., Sherrill, J., Ginsburg, G., Rynn, M., McCracken, J., Gosch, E., et al. (2010) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2010.01.009 · Cited by 369 · see citing works
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360 · see citing works
Child/Adolescent Anxiety Multimodal Study (CAMS): rationale, design, and methods
Compton, S. N., Walkup, J. T., Albano, A. M., Piacentini, J. C., Birmaher, B. B., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J. T., WASLICK, B. D., et al. (2010) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-4-1 · Cited by 337 · see citing works
The Pediatric Anxiety Rating Scale (PARS): Development and Psychometric Properties
Riddle, M., Ginsburg, G. S., Walkup, J., Labellarte, M. J., Pine, D. S., Davies, M., Greenhill, L., Sweeney, M., KLEIN, R. G., Abikoff, H., et al. (2002) · Institutional Research Information System University of Turin (University of Turin) · doi:10.1097/01.chi.0000020259.43550.f4 · Cited by 331 · see citing works
Developmental epidemiology of anxiety disorders
Beesdo-Baum, K., & Knappe, S. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.05.001 · Cited by 330 · see citing works
Meta-analysis of the dose-response relationship of SSRI in obsessive–compulsive disorder
Bloch, M. H., McGuire, J., Landeros-Weisenberger, A., Leckman, J. F., & Pittenger, C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.50 · Cited by 317 · see citing works
Rynn, M. A., Siqueland, L., & Rickels, K. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2008 · Cited by 316 · see citing works
Assessment and Treatment of Anxiety Disorders in Children and Adolescents
Wehry, A. M., Beesdo‐Baum, K., Hennelly, M. M., Connolly, S. D., & Strawn, J. R. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0591-z · Cited by 289 · see citing works
Self-citationWagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240 · see citing works
Brent, D. A., Emslie, G. J., Clarke, G. N., Asarnow, J., Spirito, A., Ritz, L., Vitiello, B., Iyengar, S., Birmaher, B., Ryan, N. D., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08070976 · Cited by 235 · see citing works
Wang, Z., Whiteside, S. P. H., Sim, L., Farah, W., Morrow, A. S., Alsawas, M., Barrionuevo, P., Tello, M., Asi, N., Beuschel, B., et al. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.3036 · Cited by 234 · see citing works
Furukawa, T. A., Salanti, G., Atkinson, L. Z., Leucht, S., Ruhe, H. G., Turner, E. H., Chaimani, A., Ogawa, Y., Takeshima, N., Hayasaka, Y., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010919 · Cited by 214 · see citing works
GELLER, D. A., Donnelly, C. L., López, F. A., Rubin, R. L., Newcorn, J. H., Sutton, V. K., Bakken, R., Paczkowski, M., Kelsey, D. K., & Sumner, C. R. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180ca8385 · Cited by 208 · see citing works
Bayesian Nets and Causality: Philosophical and Computational Foundations
Williamson, J. (2005) · Cited by 199 · see citing works
Jakubovski, E., Varigonda, A. L., Freemantle, N., Taylor, M. J., & Bloch, M. H. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15030331 · Cited by 197 · see citing works
Rynn, M. A., Riddle, M. A., Yeung, P. P., & Kunz, N. R. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.2.290 · Cited by 185 · see citing works
Strawn, J. R., Welge, J. A., Wehry, A. M., Keeshin, B., & Rynn, M. A. (2015) · Depression and Anxiety · doi:10.1002/da.22329 · Cited by 183 · see citing works
Self-citationA Randomized Controlled Trial of Venlafaxine ER Versus Placebo in Pediatric Social Anxiety Disorder
March, J. S., Entusah, A. R., Rynn, M., Albano, A. M., & Tourian, K. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.02.025 · Cited by 156 · see citing works
Husky, M. M., Olfson, M., He, J., Nock, M. K., Swanson, S. A., & Merikangas, K. R. (2012) · Psychiatric Services · doi:10.1176/appi.ps.201200058 · Cited by 153 · see citing works
Murrin, L. C., Sanders, J. D., & Bylund, D. B. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.028 · Cited by 152 · see citing works
Neural Substrates of Childhood Anxiety Disorders
Blackford, J. U., & Pine, D. S. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.05.002 · Cited by 138 · see citing works
Walkup, J. T. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091059 · Cited by 112 · see citing works
Asselmann, E., Wittchen, H. ‐., Lieb, R., & Beesdo‐Baum, K. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12792 · Cited by 112 · see citing works
Strawn, J. R., Prakash, A., Zhang, Q., Pangallo, B. A., Stroud, C., Cai, N., & Findling, R. L. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.01.008 · Cited by 110 · see citing works
Self-citationEmslie, G. J., Prakash, A., Zhang, Q., Pangallo, B. A., Bangs, M. E., & March, J. S. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0096 · Cited by 104 · see citing works
Secondary depression in severe anxiety disorders: a population-based cohort study in Denmark
Meier, S. M., Petersen, L., Mattheisen, M., Mors, O., Mortensen, P. B., & Laursen, T. M. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00092-9 · Cited by 98 · see citing works
Ding, Y., Naganawa, M., Gallezot, J., Nabulsi, N., Lin, S.-F., Ropchan, J. R., Weinzimmer, D. P., McCarthy, T. J., Carson, R. E., Huang, Y. H., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.08.001 · Cited by 93 · see citing works
Issari, Y., Jakubovski, E., Bartley, C. A., Pittenger, C., & Bloch, M. H. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09758 · Cited by 92 · see citing works
Varigonda, A. L., Jakubovski, E., & Bloch, M. H. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.07.768 · Cited by 92 · see citing works
A comparison of model selection criteria
Mills, J. A., & Prasad, K. (1992) · Econometric Reviews · doi:10.1080/07474939208800232 · Cited by 89 · see citing works
Self-citationReinblatt, S. P., dosReis, S., Walkup, J. T., & Riddle, M. A. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.040 · Cited by 81 · see citing works
Antidepressants and Psychostimulants in Pediatric Populations: Is there an Association with Mania?
Goldsmith, M., Singh, M., & Chang, K. (2011) · Pediatric Drugs · doi:10.2165/11591660-000000000-00000 · Cited by 79 · see citing works
Child/Adolescent Anxiety Multimodal Study: Evaluating Safety
Rynn, M. A., Walkup, J. T., Compton, S. N., Sakolsky, D. J., Sherrill, J. T., Shen, S., Kendall, P. C., McCracken, J. T., Albano, A. M., Piacentini, J. C., et al. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.12.015 · Cited by 71 · see citing works
Strawn, J. R., Adler, C. M., McNamara, R. K., Welge, J. A., Bitter, S. M., Mills, N. P., Barzman, D. H., Cerullo, M. A., Chang, K. D., Strakowski, S. M., et al. (2014) · Bipolar Disorders · doi:10.1111/bdi.12113 · Cited by 70 · see citing works
Self-citationThe Relevance of Pharmacokinetic Studies in Designing Efficacy Trials in Juvenile Major Depression
Findling, R. L., McNamara, N. K., Stansbrey, R. J., Feeny, N. C., Young, C. M., Peric, F. V., & Youngstrom, E. A. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.131 · Cited by 63 · see citing works
Kruschke, J. K. (2012) · British Journal of Mathematical and Statistical Psychology · doi:10.1111/j.2044-8317.2012.02063.x · Cited by 63 · see citing works
Sakolsky, D. J., Perel, J. M., Emslie, G. J., Clarke, G. N., Wagner, K. D., Vitiello, B., Keller, M. B., Birmaher, B. B., Asarnow, J. R., Ryan, N. D., et al. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318204b117 · Cited by 63 · see citing works
Treatment of Separation, Generalized, and Social Anxiety Disorders in Youths
Mohatt, J. W., Bennett, S. M., & Walkup, J. T. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101337 · Cited by 61 · see citing works
Psychopharmacologic Treatment of Children and Adolescents with Anxiety Disorders
Strawn, J. R., Sakolsky, D. J., & Rynn, M. A. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.05.003 · Cited by 57 · see citing works
Self-citationNeurobiology of Pediatric Anxiety Disorders
Strawn, J. R., Dominick, K. C., Patino, L. R., Doyle, C. D., Picard, L. S., & Phan, K. L. (2014) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-014-0014-1 · Cited by 57 · see citing works
Self-citationFindling, R. L., Nucci, G., Piergies, A. A., Goméni, R., Bartolic, E. I., Fong, R., Carpenter, D. J., Leeder, J. S., Gaedigk, A., & Danoff, T. M. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300960 · Cited by 57 · see citing works
Varigonda, A. L., Jakubovski, E., Taylor, M. J., Freemantle, N., Coughlin, C. G., & Bloch, M. H. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.05.004 · Cited by 55 · see citing works
Strawn, J. R., Compton, S. N., Robertson, B., Albano, A. M., Hamdani, M., & Rynn, M. A. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0132 · Cited by 55 · see citing works
Self-citationStrawn, J. R., Mills, J. A., Cornwall, G. J., Mossman, S. A., Varney, S. T., Keeshin, B. R., & Croarkin, P. E. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0060 · Cited by 50 · see citing works
Self-citationReid, A. M., McNamara, J. P. H., Murphy, T. K., Guzick, A. G., Storch, E. A., Geffken, G. R., & Bussing, R. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.10.006 · Cited by 38 · see citing works
Strawn, J. R., Dobson, E. T., Mills, J. A., Cornwall, G. J., Sakolsky, D. J., Birmaher, B. B., Compton, S. N., Piacentini, J. C., McCracken, J. T., Ginsburg, G. S., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0198 · Cited by 36 · see citing works
Self-citationZhou, X., Cipriani, A., Zhang, Y., Cuijpers, P., Hetrick, S. E., Weisz, J. R., Pu, J., Giovane, C. D., Furukawa, T. A., Barth, J., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016608 · Cited by 31 · see citing works
Association of Childhood Anxiety Disorders and Quality of Life in a Primary Care Sample
Ramsawh, H. J., & Chavira, D. A. (2016) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0000000000000296 · Cited by 27 · see citing works
Dobson, E. T., & Strawn, J. R. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0192 · Cited by 23 · see citing works
Self-citationPharmacokinetics and Safety of Vortioxetine in Pediatric Patients
Findling, R. L., Robb, A. S., DelBello, M. P., Huß, M., McNamara, N., Sarkis, E. H., Scheffer, R. E., Poulsen, L. H., Chen, G., Lemming, O. M., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0155 · Cited by 20 · see citing works
Mantovani, M., Dooley, D. C., Weyerbrock, A., Jackisch, R., & Feuerstein, T. J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00478.x · Cited by 19 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [26]Strawn JR Welge JA Wehry AM Keeshin B Rynn MA Efficacy and Tolerability of Antidepressants in Pediatric Anxiety Disorders: a Systematic Review and Meta-Analysis Depress Anxiety 2015 32 3 149 157 25449861 PMC4514767
- [69]Varigonda AL Jakubovski E Taylor MJ Freemantle N Coughlin C Bloch MH Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder J Am Acad Child Adolesc Psychiatry 2015 54 7 557 564 26088660
Cited by
Sorted by citations
Walter, H. J., Bukstein, O. G., Abright, A. R., Keable, H., Ramtekkar, U., Ripperger-Suhler, J., & Rockhill, C. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.05.005 · Cited by 335 · see citing works
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214 · see citing works
Self-citationAlmeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177 · see citing works
Research Review: Pediatric Anxiety Disorders—What Have We Learnt in the Last 10 Years?
Strawn, J. R., Lu, L., Peris, T. S., Levine, A., & Walkup, J. T. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13262 · Cited by 168 · see citing works
Self-citationSystematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131 · see citing works
Taliaz, D., Spinrad, A., Barzilay, R., Barnett-Itzhaki, Z., Averbuch, D., Teltsh, O., Schurr, R., Darki-Morag, S., & Lerer, B. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01488-3 · Cited by 93 · see citing works
Vaughn, S., Strawn, J., Poweleit, E., Sarangdhar, M., & Ramsey, L. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070615 · Cited by 40 · see citing works
Self-citationStrawn, J. R., & Levine, A. (2020) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2020.100024 · Cited by 30 · see citing works
Self-citationPsychological and Psychiatric Comorbidities in Youth with Serious Physical Illness
Nibras, S., Kentor, R., Masood, Y., Price, K., Schneider, N. M., Tenenbaum, R. B., & Calarge, C. (2022) · Children · doi:10.3390/children9071051 · Cited by 25 · see citing works
Claudio‐Campos, K., Padrón, A., Jerkins, G., Nainaparampil, J., Nelson, R., Martin, A., Wiisanen, K., Smith, D. M., Strekalova, Y., Marsiske, M., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.12914 · Cited by 24 · see citing works
Stefánsdóttir, Í. H., Ivarsson, T., & Skarphedinsson, G. (2023) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2075460 · Cited by 19 · see citing works
Advances in Pharmacotherapy for Pediatric Anxiety Disorders
Nicotra, C. M., & Strawn, J. R. (2023) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2023.02.006 · Cited by 16 · see citing works
Self-citationPeterson, B. S., West, A. E., Weisz, J. R., Mack, W. J., Kipke, M. D., Findling, R. L., Mittman, B. S., Bansal, R., Piantadosi, S., Takata, G., et al. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03314-y · Cited by 13 · see citing works
When is it appropriate to treat children with social anxiety, pharmacologically?
Snir, A., Moskow, D. M., & Hofmann, S. G. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1948015 · Cited by 3 · see citing works
The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder
Castagna, P. J., Farahdel, E., Potenza, M. N., & Crowley, M. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2199921 · Cited by 3 · see citing works
The risks versus the benefits of pharmacological intervention in social anxiety disorder in children
Hofmann, S. G., Kasch, C., Pereira, B., Barbosa, C., & Andreoli, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2461763 · Cited by 2 · see citing works
- Authors
- Strawn, J. R., Mills, J. A., Sauley, B. A., & Welge, J. A.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- University of Cincinnati (US)
- Corresponding author
- Strawn, Jeffrey R.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 57
- Issue
- 4
- Pages
- 235-244.e2
- ISSN
- 0890-8567 (ISSN-L)
- PMC
- PMC5877120
- OpenAlex
- W2791558269
- Cited by
- 98
- References
- 71
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 16 · 2023: 14 · 2022: 10 · 2021: 17 · 2020: 7 · 2019: 11 · 2018: 8
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5k23mh106037-04)
- National Institute of Mental Health (K23-MH106037)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Keywords
- childhood anxiety disorders, antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressant dose, treatment response trajectories, symptom severity, Bayesian updating, generalized anxiety disorder, separation anxiety disorder, social anxiety disorder
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Adolescent, Anxiety Disorders, Humans, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
